EARLY ESTABLISHMENT OF HIV 1 LATENCY IN RESTING CD4+ T CELLS

潜伏感染的静息CD 4 + T细胞的存在 已经证明了携带有复制能力的HIV-1的细胞 在接受抗逆转录病毒治疗的慢性感染者中 是吗？以及那些正在接受高度活跃的 抗逆转录病毒疗法（HAART）。我们调查是否 建立潜伏感染的CD 4 + T细胞库可以 在初次感染后早期开始HAART可阻断。 我们的研究表明，尽管成功地控制了 感染者开始HAART后的血浆病毒血症 个人早在10天后的症状发作， 原发性HIV-1感染，潜伏感染的产生，静息 携带整合的HIV-1 DNA以及感染性的CD 4 + T细胞 HIV-1没有得到预防。此外， 研究时HAART的持续时间（范围： 0.2至17个月）或HAART开始后的时间 出现原发性HIV-1感染症状（范围：0.3 - 4 月）和携带以下任一项的静息CD 4 + T细胞的频率 整合的HIV-1 DNA或传染性病毒。这些结果 强调了潜在油气藏形成的迅速性 在原发性HIV-1感染中， 在原发性感染期间进行治疗可以防止 潜伏感染的静息CD 4 + T细胞池， 在血浆病毒血症变得明显后开始。

The presence of latently infected, resting CD4+ T cells carrying replication-competent HIV-1 has been demonstrated in chronically infected individuals who are anti-retroviral therapy na?ve as well as in those who are receiving highly active anti-retroviral therapy (HAART). We investigated whether the establishment of a pool of latently infected CD4+ T cells can be blocked by early initiation of HAART following primary infection. Our study demonstrates that despite the successful control of plasma viremia following initiation of HAART in infected individuals as early as 10 days after the onset of symptoms of primary HIV-1 infection, the generation of latently infected, resting CD4+ T cells carrying integrated HIV-1 DNA as well as infectious HIV-1 was not prevented. Furthermore, there was no correlation between either the duration of HAART at the time of study (range: 0.2 to 17 months) or the time of initiation of HAART after the onset of symptoms of primary HIV-1 infection (range: 0.3 to 4 months) and the frequencies of resting CD4+ T cells carrying either integrated HIV-1 DNA or infectious virus. These results underscore the rapidity with which latent reservoirs are established in primary HIV-1 infection and indicate that it is unlikely that early treatment during primary infection can prevent establishment of a pool of latently infected, resting CD4+ T cells as long as treatment is initiated after plasma viremia becomes evident.